The London startup has raised backing from Aper Ventures and co-investors to support its expansion into the UK and German markets.
"Our robots are highly efficient and reliable; their real edge lies in their ability to work harmoniously with humans in crowded settings, in real-time. We’ve redesigned the traditional machine, enabling each robot to turn in place, making it the most agile autonomous scrubber available."
The funding from the Development Bank of Wales supports the construction of 44 new homes in Newtown.
"As a local family-run company, we pride ourselves on building high-quality and good value new homes. Oaks Meadow offers local people the opportunity to buy in their community, be that their place of birth, residency or employment which is why we were keen to make sure that we partnered with a funder who understood the local area."
The investment was led by Verdane to support the company as it grows its commercial solar footprint across Europe.
"Securing this €26 million funding from Verdane marks a pivotal moment for UrbanVolt as we set our sights on an ambitious European expansion. We are thrilled to have the support of Verdane, a renowned specialist growth investor and fellow certified B Corp company, who share our vision for a sustainable future."
The company has raised €10m to add 280 new vehicles and extend its services across urban and rural locations in Ireland.
"At GoCar, we believe in creating a community-led approach to mobility, becoming an integral part of the fabric of localities across the country. Our investment reflects our dedication to increasing the availability of sustainable and flexible transport options to meet the evolving needs of our customers. Over the past three years, we have been evolving beyond our legacy urban hubs in Dublin, Cork, Limerick and Galway and we are committed to making GoCar available in 24 counties across ROI by the end of 2023."
The company will apply its machine learning technology to improve the production of oligonucleotide therapeutics in partnership with CPI.
"We are really excited to be working with Intellegens on this project to help harness the potential of oligonucleotides to treat a variety of conditions. Oligonucleotides are complex molecules and the process of bringing them to market is costly, meaning very few companies are able to harness this potentially life-saving and life-changing technology. Through CPI’s Medicines Manufacturing Innovation Centre, we will look to bring together a community of experts from the pharmaceutical and technology companies to support the development of the Alchemite tools, reducing development times and improving manufacturability of oligonucleotide therapeutics."